Selegiline — Membership Pricing

Other medications in Neurological

• Siponimod
• Sumatriptan
• Teriflunomide
• Tiagabine
• Trihexyphenidyl
• Ubrogepant
• Valproate IV
• Vigabatrin

About Selegiline

Selegiline is a vital medication often prescribed for Parkinson's disease and sometimes for depression. Understanding your treatment options and their associated costs is crucial for long-term health management. With TheDrugClub, you can access significant discounts on prescriptions like Selegiline, making essential medications more accessible and affordable for you and your family.

Selegiline is a prescription medication primarily used to manage the symptoms of Parkinson's disease. It's often prescribed as an adjunct therapy to levodopa/carbidopa, helping to extend the effectiveness of these medications. In some cases, it may be used alone in the early stages of Parkinson's. Beyond Parkinson's, selegiline is also available in a transdermal patch form (Emsam) for the treatment of major depressive disorder.

How Selegiline Works

At its core, selegiline works by inhibiting an enzyme called monoamine oxidase B (MAO-B) in the brain. MAO-B is responsible for breaking down dopamine, a neurotransmitter that plays a

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Selegiline is approved for (FDA label)

EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . EMSAM ® (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: May 15, 2020.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Selegiline (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . EMSAM is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis [see Contraindications (4) and Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • EMSAM is contraindicated in patients less than 12 years of age ( 4 , 8.4 ).

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Selegiline (FDA label)

EMSAM (selegiline transdermal system) is supplied as 6 mg per 24 hours (20 mg per 20 cm 2 ), 9 mg per 24 hours (30 mg per 30 cm 2 ) and 12 mg per 24 hours (40 mg per 40 cm 2 ) transdermal systems (TDS). EMSAM 6 mg per 24 hours is a translucent TDS printed with ‘EMSAM ® 6mg/24h’. EMSAM 9 mg per 24 hours is a translucent TDS printed with ‘EMSAM ® 9mg/24h’. EMSAM 12 mg per 24 hours is a translucent TDS printed with ‘EMSAM ® 12mg/24h’. Transdermal System: 6 mg per 24 hours, 9 mg per 24 hours and 12 mg per 24 hours ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Selegiline (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the label. • Suicidal Thoughts and Behaviors [see Warnings and Precautions (5.1) ] . • Serotonin Syndrome [see Contraindications (4) and Warnings and Precautions (5.2) ] . • Blood Pressure Elevation [see Warnings and Precautions (5.3) ] . • Activation of Mania/Hypomania [see Warnings and Precautions (5.4) ] . • External Heat [see Warnings and Precautions (5.5) ] . • Adverse Reactions occurring at an incidence of 2% or More Among EMSAM-Treated Patients and greater than placebo: Application site reaction, headache, insomnia, diarrhea, dry mouth, dyspepsia, rash, pharyngitis, sinusitis ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Selegiline (FDA label)

• EMSAM (selegiline transdermal system) is contraindicated with selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline, and paroxetine); serotonin and norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine and duloxetine); the tricyclic antidepressants clomipramine and imipramine, the opiate analgesics meperidine, tramadol, methadone, pentazocine, and propoxyphene; and the antitussive agent dextromethorphan because of a risk of serotonin syndrome when EMSAM is used with these agents [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] . • Carbamazepine is contraindicated with EMSAM because of a possible increased risk of hypertensive crisis [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] .

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Selegiline (FDA label)

• Tyramine-Induced Hypertensive Crisis: Patients receiving EMSAM 9 mg per 24 hours and 12 mg per 24 hours should follow the recommended dietary modifications ( 5.3 ). • Blood Pressure Elevation Related to Concomitant Medication: monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, or cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine). If a hypertensive crisis occurs, EMSAM should be discontinued immediately and therapy to lower blood pressure should be instituted immediately ( 5.3 ). • Activation of Mania/Hypomania: Screen patients for bipolar disorder ( 5.4 ).

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Selegiline (FDA label)

7.1 Serotonergic Drugs Serious, sometimes fatal, central nervous system (CNS) toxicity referred to as the “serotonin syndrome” has been reported with the combination of nonselective MAOIs and serotonergic drugs. Use of EMSAM with these drugs is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2) ] . 7.2 Tyramine EMSAM has the capacity to inhibit intestinal MAO, which is responsible for the catabolism of tyramine in food and beverages. As a result of this inhibition, large amounts of tyramine may enter the systemic circulation and precipitate a sudden, large rise in blood pressure or hypertensive crisis [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.2) ] . A diet low in tyramine content may be necessary to avoid this interaction.

Source: FDA prescribing information (DailyMed). Set ID: b891bd9f-fdb8-4862-89c5-ecdd700398a3. SPL document ID: 97cc8813-9de7-42f5-89dd-c46f8b6730fa. Label effective date: May 15, 2020. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.